文献速递血栓与止血

内科疾病合并癌症患者延长血栓预防的系统综述与荟萃分析

Extended thromboprophylaxis for medically ill patients with cancer: a systemic review and meta-analysis.
PubMed 文献 · Blood Adv · 2021-01-01

本文系统检索MEDLINE、EMBASE和Cochrane CENTRAL数据库,纳入4项随机对照试验共3655例活动性或既往癌症的内科疾病住院患者,比较延长与标准疗程血栓预防。结果显示延长预防未降低静脉血栓栓塞事件率(OR 0.85,95%CI 0.61-1.18),但大出血和临床相关非大出血显著增加(OR 2.10,95%CI 1.33-3.35)。

要点

  • 延长血栓预防未显著降低癌症内科住院患者静脉血栓栓塞事件率。
  • 延长预防组大出血及临床相关非大出血风险约为标准疗程组的2.10倍。
  • 癌症内科住院患者延长血栓预防需权衡出血风险,不宜常规延长。

核心结论

  • 在内科疾病住院的癌症患者中,延长血栓预防与静脉血栓栓塞事件减少无关,反而增加出血风险。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE、EMBASE和Cochrane CENTRAL数据库,纳入4项随机对照试验的癌症亚组,共3655例活动性或既往癌症的内科疾病住院患者。
  • 研究方案在PROSPERO注册(#CRD42020209333)。

主要发现

  • 延长疗程与标准疗程组的静脉血栓栓塞事件率相似(OR 0.85;95%CI 0.61-1.18;I2=0%)。
  • 延长血栓预防组的大出血和临床相关非大出血发生率显著更高(OR 2.10;95%CI 1.33-3.35;I2=8%)。

临床怎么用

  • 对内科疾病住院的癌症患者,延长血栓预防不应仅以降低静脉血栓栓塞为目的常规使用,需个体化评估出血风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hospitalized medically ill patients with cancer are at increased risk of both venous thromboembolism and bleeding. The safety and efficacy of extended thromboprophylaxis in patients with cancer are unclear. We conducted a systematic review and meta-analysis of the literature using of MEDLINE, EMBASE, and the Cochrane CENTRAL databases to identify cancer subgroups enrolled in randomized controlled trials evaluating extended thromboprophylaxis following hospitalization. The primary outcomes were symptomatic and incidental venous thromboembolic events and hemorrhage (major hemorrhage and clinically relevant nonmajor bleeding). Four randomized controlled trials reported the outcomes of extended thromboprophylaxis in 3655 medically ill patients with active or history of cancer. The rates of venous thromboembolic events were similar between the extended-duration and standard-duration groups (odds ratio [OR], 0.85; 95% confidence interval [CI], 0.61-1.18; I2 = 0%). However, major and clinically relevant nonmajor bleeding occurred significantly more frequently in the extended-duration thromboprophylaxis group (OR, 2.10; 95% CI, 1.33-3.35; I2 = 8%). Extended thromboprophylaxis in hospitalized medically ill patients with cancer was not associated with a reduced rate of venous thromboembolic events but was associated with increased risk of hemorrhage. This study protocol was registered on PROSPERO as #CRD42020209333.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Osataphan S, Patell R, Chiasakul T, et al. Extended thromboprophylaxis for medically ill patients with cancer: a systemic review and meta-analysis. Blood Adv. 2021. PMID: 33861298. doi:10.1182/bloodadvances.2020004118

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。